January 2026 Research Update

This month added several early but practical-looking ideas for finding wild-type ATTR amyloidosis (wtATTR) sooner, especially when it can look like ordinary heart failure in older adults. Across these studies, different tests picked up different parts of the picture: some aimed to detect previously unrecognized disease in the community, while others looked for patterns that help separate wtATTR from similar conditions. The shared message is that earlier detection may be possible, but the best approach and real-world value still depend on cost, accuracy, and follow-through after a positive screen. [1] [2] [3] [4]

A large screening effort in 1000 adults aged 65 to 90 found a small number of new wtATTR heart amyloidosis cases, and it also uncovered other heart and kidney problems during testing. The study reported that the overall cost-effectiveness changed a lot depending on how the benefits of those extra findings were counted, and on the assumed cost of tafamidis. For patients, this highlights a real-world tension: screening may find disease and other conditions earlier, but it can be expensive and its value depends on what happens after a diagnosis is made. [1]

Two studies suggested additional tools that might help flag wtATTR when symptoms and standard tests are not clear. One ECG study found that certain electrical recovery timing measures were longer in ATTRwt cardiomyopathy than in healthy controls, and they tracked with markers of heart strain and remodeling. A separate study used fingernail small-vessel imaging with computer analysis and reported moderate accuracy in distinguishing ATTRwt from non-amyloid HFpEF, and higher accuracy for sorting people into more versus less severe disease groups within ATTRwt. [2] [4]

Carpal tunnel surgery specimens also continued to look like a potential early clue rather than just an orthopedic problem. In 551 people having carpal tunnel release, amyloid was found in 9% of ligament samples and was usually ATTR type, and a subset later turned out to have early-stage ATTR cardiomyopathy. This supports the idea that wtATTR may show up outside the heart first, but it also shows that an amyloid finding in the wrist does not automatically mean a person already has heart involvement. [3]

For patients and caregivers, these studies mainly add to early-detection research rather than changing what is routinely done right now. They help clarify that wtATTR can sometimes be uncovered through structured screening or through patterns on tests done for other reasons, and that newer approaches (like fingertip small-vessel imaging with computer scoring) are being explored to reduce missed or delayed diagnoses. What remains uncertain is how well these approaches work across different clinics and populations, and whether the benefits justify the added testing and costs. [1] [2] [3] [4]

Several studies this month focused on why two people with wtATTR can feel and function very differently, and how testing might better capture that range. The overall pattern is that single, familiar numbers often miss important differences: more detailed heart ultrasound measures, more detailed amyloid scan mapping, and physiologic testing under stress each revealed problems that could be overlooked in simpler assessments. For patients, this supports a more nuanced view of the disease: symptoms and risk can reflect changes in multiple parts of heart function and circulation, not only the usual ejection fraction. [5] [6] [7]

In a 256-person wtATTR cardiomyopathy cohort, left and right heart pumping problems were common at diagnosis, and some people had abnormal strain and low forward flow even when ejection fraction looked preserved. The study also found that a right-heart measure (TAPSE) added prognostic information, with the best outcomes reported in people with both preserved ejection fraction and preserved TAPSE. In plain language, this suggests that looking at both sides of the heart and at how effectively blood is being pushed forward may better reflect how serious the condition is for an individual. [5]

A smaller 33-person study suggested that more detailed mapping of technetium PYP scan uptake across both the left and right ventricles related to later cardiovascular events. Adding right-ventricle uptake measures improved prediction beyond a staging system or left-heart strain alone. For patients, this is an early signal that where amyloid tracer collects in the heart, not just whether it is present, may carry useful information if confirmed in larger groups. [6]

A physiology study comparing wtATTR patients with HFpEF to HFpEF controls found a specific difference in blood pressure control during simulated standing stress. Heart rate and central blood volume shifts looked similar, but wtATTR patients had weaker tightening of peripheral blood vessels and a larger drop in blood pressure at higher stress levels. This helps explain why some people with wtATTR may have more lightheadedness or orthostatic intolerance, because the problem may be in how blood vessels respond rather than only in heart pumping. [7]

For patients, these studies mostly matter as improved understanding and better measurement rather than direct changes in treatment. They help clarify that wtATTR can affect both the heart and the blood vessel system, and that a person can have meaningful functional impairment even when a common heart number like ejection fraction is still in a "preserved" range. What remains uncertain is how these more detailed measures should be used across different clinics, and which ones will prove most reliable for predicting day-to-day course and long-term outcomes. [5] [6] [7]

This month brought a mix of procedural studies, individual device case reports, and lab work aimed at new ways to address wtATTR-related heart problems. The common pattern is that several approaches are being explored to manage complications (like stroke risk or reduced heart pumping), while separate laboratory research is looking for ways to break down existing amyloid deposits. Together, these studies expand the menu of possibilities being studied, but most of the evidence here is still early and not yet proof of broad benefit. [8] [9] [10] [11]

In a 21-person single-center cohort of cardiac amyloidosis patients (mostly wtATTR) undergoing left atrial appendage closure (a procedure intended to reduce stroke risk from atrial fibrillation), the procedure was usually successful and there were no complications around the time of the procedure. Over a median 24-month follow-up, the report noted some minor leaks around the device and a small number of strokes or TIAs, and it also reported major bleeding in two patients while on anticoagulation after the procedure. For patients, this provides real-world information about what has been observed in a small amyloidosis group, including that bleeding and stroke events can still occur during follow-up. [8]

Two single-patient reports described cardiac contractility modulation (CCM), a device therapy designed to improve heart contraction, in wtATTR with reduced pumping function. In one person, ejection fraction improved over about a year and tafamidis was started afterward, and in another, a CCM device was co-implanted with a leadless pacemaker and the person reported better functional class and no heart-failure hospitalizations at 1 year. For patients, these cases show what is possible in individual circumstances, but they do not yet show how often similar results happen in broader wtATTR populations. [9] [10]

A laboratory study identified PGG, a compound derived from pomegranate extracts, that disrupted already-formed transthyretin amyloid fibrils in test-tube experiments and reduced deposits in a small animal model (worms). It also disrupted patient-derived cardiac TTR fibrils outside the body, and the breakdown products were not toxic to a nerve cell line in the lab. For patients, this is early-stage research aimed at clearing existing amyloid deposits, but it does not show whether PGG would be safe or effective in people. [11]

For patients and caregivers, this group of studies is mainly about early evidence and feasibility rather than established outcomes. The left atrial appendage closure report adds real-world follow-up information in a small amyloidosis cohort, including that procedure success can be high while bleeding or stroke events may still be seen later. The CCM device cases and the pomegranate-derived compound study are best viewed as signals of ideas under investigation, with major uncertainty about how well they translate to typical wtATTR patients and what risks or benefits would look like in larger studies. [8] [9] [10] [11]

This month included several case reports that highlight how wtATTR is sometimes discovered in unexpected ways and how unusual courses can unfold. Taken together, these cases reinforce that imaging can uncover wtATTR incidentally, that scan patterns may change over time in some individuals, and that rare situations (like a donor heart with amyloid) can complicate expectations. For patients, these reports are useful for awareness and understanding, but they cannot predict what will happen for most people. [12] [13] [14]

Two breast cancer survivors were diagnosed with wtATTR cardiomyopathy after incidental heart uptake was seen on bone scans done for cancer-related reasons, and the diagnosis was confirmed with dedicated heart imaging and biopsy. The report emphasized that incidental cardiac uptake on these scans can be a clue worth following up, and it discussed common pitfalls in interpretation. For patients, this helps explain why an unexpected scan finding during unrelated care can sometimes be the first step toward a wtATTR diagnosis. [12]

Another case described a 90-year-old woman with heart uptake on a PYP scan and additional uptake in the rectum and a skeletal muscle, with reduced or absent uptake after 22 months of tafamidis. The report raised the possibility that imaging signals can change with treatment in some people, while also noting that not all extracardiac uptake was confirmed by tissue testing. For patients, this is a single-person observation that suggests a question for future studies: whether scan uptake can be used to track disease over time in a reliable way. [13]

A separate case described a heart transplant recipient who unknowingly received a donor heart with wtATTR amyloidosis, with progression of amyloid in the transplanted heart over more than 7 years. The course included recurrent heart failure and the patient later died, and autopsy showed extensive amyloid without evidence of rejection or coronary vasculopathy. For patients, this is a rare scenario that mainly highlights the limits of donor screening and how wtATTR can progress in heart tissue over time. [14]

For patients, these cases mostly add context and awareness rather than generalizable expectations. They help clarify that wtATTR can be detected incidentally on scans performed for other reasons, and that imaging findings may sometimes change over time in an individual, but it is not yet clear how often that happens or what it means. The transplant case is an uncommon situation, and it is most relevant as a reminder that unusual pathways to wtATTR progression exist and are still being documented. [12] [13] [14]

One cohort study this month compared wild-type ATTR to hereditary ATTR and suggested that these are not just the same disease in different people. The overall pattern was that mutation carriers were younger and, in this cohort, tended to have better functional capacity and different heart and blood vessel measurements than those with wtATTR. For patients, this helps explain why research studies often separate these groups, because their typical starting points and disease features can differ. [15]

In this 39-person cohort, measurements were taken before and 6 months after starting tafamidis, and the authors reported genotype-related differences in heart remodeling and arterial stiffness. They noted higher arterial stiffness in hereditary ATTR at baseline and follow-up with a trend toward improvement after treatment, and they reported a trend toward left-ventricular wall thickness regression in wtATTR that was not seen in hereditary ATTR. For patients, this is a short follow-up window, but it adds to the idea that what changes over time may not look identical across ATTR subtypes. [15]

For patients and caregivers, this study mainly adds understanding rather than offering direct take-home actions. It helps clarify that wtATTR and hereditary ATTR can differ in age of presentation, exercise capacity, and heart and blood vessel patterns, which may influence how studies interpret results and design future trials. What remains uncertain is how these differences play out over longer periods and across more diverse groups, since this was a small cohort with only 6 months of follow-up after tafamidis. [15]